<DOC>
	<DOCNO>NCT00727064</DOCNO>
	<brief_summary>The purpose study determine relative difference Pharmacokinetics ( PK ) extensive metabolizers ( EMs ) poor metabolizers ( PMs ) desvenlafaxine SR venlafaxine ER single dose administer .</brief_summary>
	<brief_title>Study Evaluating Pharmacokinetics Venlafaxine Extended-Release ( ER ) Desvenlafaxine Succinate Sustained-Release ( DVS SR ) 50 mg Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Venlafaxine Hydrochloride</mesh_term>
	<mesh_term>Desvenlafaxine Succinate</mesh_term>
	<criteria>Healthy men woman age 18 55 year . Healthy determine investigator basis medical history physical examination , laboratory test result , vital sign , 12lead electrocardiogram ( ECG ) . History nonsmoker least 1 year . Subjects either extensive CYP2D6 metabolizers normal complement 1 2 fully active enzyme gene allele poor CYP2D6 metabolizers ( lack active enzyme gene allele ) via genetic test blood sample . Presence history significant cardiovascular , hepatic , renal , respiratory , gastrointestinal , endocrine , immunologic , dermatologic , hematologic , neurologic , psychiatric disease severe condition ear , eye throat ( glaucoma increase intraocular pressure ) . Known suspected alcohol abuse consumption 2 standard unit per day ( standard unit equal 12 ounce beer , 1Â½ ounce 80proof alcohol , 6 ounce wine ) within past 6 month . Known suspect current abuse prohibit drug substance . Use hormonal therapy within 30 day study day 1 end partial inpatient confinement period .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>May 2010</verification_date>
	<keyword>Healthy Subjects</keyword>
</DOC>